Julie Vose, MD, MBA, on the Use of CAR T-Cell Therapy in Lymphomas

Video

Julie Vose, MD, MBA, a professor of internal medicine in the Division of Oncology and Hematology at the University of Nebraska Medical Center discussed the benefits of CAR T-cell for patients with follicular lymphoma.

At the 2021 American Society of Clinical Oncology Annual Meeting, CancerNetwork® spoke with Julie Vose, MD, MBA, a professor of internal medicine in the Division of Oncology and Hematology at the University of Nebraska Medical Center, about the numerous trials that read out at the meeting pertaining to CAR T-cell therapy in patients with hematologic malignancies. Vose discusses the benefit of this therapy for patients with follicular lymphoma in addition to how it may affect patients with other lymphomas.

Transcript:

[One category that really excites me is] the use of CAR T-cells for other types of lymphomas other than diffuse large B-cell. There were a couple of different trials that were presented [at ASCO] looking at CAR T-cells for follicular lymphoma. That has shown some follow up information, and we can see that those specific types of CAR T-cells now can be applied to other types of lymphomas and have some good outcomes. We are looking forward to applying that [technology] to other types of lymphomas, as well as other malignancies.

Recent Videos
Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
Despite CD19 CAR T-cell therapy exhibiting efficacy in patients with relapsed/refractory large B-cell lymphoma, less than half achieve long-term remission.
Current findings from the phase 1/2 CaDAnCe-101 trial show no predictive factors of improved responses with BGB-16673 in patients with CLL or SLL.
More follow-up data will better elucidate the impact of frontline use of hypomethylating agents in patients with myelodysplastic syndromes.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
Related Content